Clinical Trials
19 trialsNCT07288359 2026-05-27
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
Phase 1/2 Recruiting
NCT05768139 2026-05-22
PIKALO-1
Eli Lilly and Company
Phase 1/2 Recruiting
NCT07109726 2026-05-22
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences Inc.
Phase 1/2 Recruiting
NCT07540572 2026-05-20
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
IDEAYA Biosciences
Phase 1/2 Recruiting
NCT06110793 2026-05-13
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT07287917 2026-05-12
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Aminex Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05319873 2026-05-11
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Jonsson Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT06993844 2026-05-06
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Phase 1/2 Recruiting
NCT07570966 2026-05-06
Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
Phase 1/2 Not yet recruiting
NCT06998407 2026-05-04
AVZO-023-1001
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05608252 2026-04-30
VS-6766+Abema+Fulv in Met HR+/HER- BC
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT07558733 2026-04-30
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
Faeth Therapeutics
Phase 1/2 Recruiting
NCT06726148 2026-04-27
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
Phase 1/2 Recruiting
NCT07389733 2026-04-03
A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
Phase 1/2 Recruiting
NCT05735080 2026-04-01
INX-315-01
Incyclix Bio
Phase 1/2 Recruiting
NCT05573126 2026-03-20
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Ellipses Pharma
Phase 1/2 Recruiting
NCT03424005 2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05230810 2026-03-16
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
Criterium, Inc.
Phase 1/2 Active not recruiting
NCT06736704 2026-03-13
SNV4818 in Participants With Advanced Solid Tumors
Pikavation Therapeutics, Inc.
Phase 1/2 Recruiting